Byrne Anthony L, Marais Ben J, Mitnick Carole D, Garden Frances L, Lecca Leonid, Contreras Carmen, Yauri Yaninna, Garcia Fanny, Marks Guy B
Department of Medicine, Central Clinical School, University of Sydney, Sydney, Australia.
Socios En Salud Sucursal Perú, Partners In Health, Lima, Peru.
ERJ Open Res. 2017 Jul 12;3(3). doi: 10.1183/23120541.00026-2017. eCollection 2017 Jul.
Cross-sectional studies reveal an association between tuberculosis (TB) and chronic airflow obstruction, but cannot adequately address confounding. We hypothesised that treated pulmonary TB is an independent risk factor for chronic airflow obstruction. The Pulmones Post TB cohort study enrolled participants from Lima, Peru, aged 10-70 years with a history of drug-susceptible (DS)- or multidrug-resistant (MDR)-TB who had completed treatment and were clinically cured. Unexposed participants without TB were randomly selected from the same districts. We assessed respiratory symptoms, relevant environmental exposures, and spirometric lung function pre- and post-bronchodilator. In total, 144 participants with DS-TB, 33 with MDR-TB and 161 unexposed participants were fully evaluated. Compared with unexposed participants, MDR-TB patients had lower lung volumes (adjusted mean difference in forced vital capacity -370 mL, 95% CI -644- -97) and post-bronchodilator airflow obstruction (adjusted OR 4.89, 95% CI 1.27-18.78). Participants who had recovered from DS-TB did not have lower lung volumes than unexposed participants, but were more likely to have a reduced forced expiratory volume in 1 s/forced vital capacity ratio <0.70 (adjusted OR 2.47, 95% CI 1.01-6.03). Individuals successfully treated for TB may experience long-lasting sequelae. Interventions facilitating earlier TB treatment and management of chronic respiratory disease should be explored.
横断面研究揭示了结核病(TB)与慢性气流阻塞之间的关联,但无法充分解决混杂因素问题。我们假设,经过治疗的肺结核是慢性气流阻塞的一个独立危险因素。肺结核后肺部队列研究招募了来自秘鲁利马、年龄在10至70岁之间、有药物敏感(DS)或耐多药(MDR)结核病病史且已完成治疗并临床治愈的参与者。未患结核病的未暴露参与者从同一地区随机选取。我们评估了支气管扩张剂前后的呼吸道症状、相关环境暴露和肺功能仪测定的肺功能。总共对144名DS-TB参与者、33名MDR-TB参与者和161名未暴露参与者进行了全面评估。与未暴露参与者相比,MDR-TB患者的肺容量较低(用力肺活量调整后平均差异为-370 mL,95%CI为-644至-97),支气管扩张剂后气流阻塞情况更严重(调整后OR为4.89,95%CI为1.27至18.78)。从DS-TB中康复的参与者的肺容量并不比未暴露参与者低,但1秒用力呼气量/用力肺活量比值<0.70的可能性更高(调整后OR为2.47,95%CI为1.01至6.03)。成功治疗结核病的个体可能会经历长期后遗症。应探索促进早期结核病治疗和慢性呼吸道疾病管理的干预措施。